Cellistic
Gustavo Mahler is the current Chief Executive Officer of Cellistic and Ncardia. Previously, Mahler has held various executive positions in companies such as Dynamk Capital LLC, Life Science Washington, AGC Biologics, CMC Icos Biologics, AbSci, Bayer Healthcare, and Bayer. With a strong background in Biochemistry and Business, Mahler has significant experience in leading global operations, sales, marketing, and manufacturing in the biotechnology industry.
This person is not in any offices
Cellistic
Launched in April 2022, Cellistic specializes in process development and manufacture of cell therapies based on human induced pluripotent stem cell (iPSC) technology. The company’s focus and expertise in iPSC generation and differentiation protocol development makes it well-positioned to partner with innovative cell therapy developers to establish novel advanced therapies. With more than a decade of scientific and technical knowledge transfer from sister company Ncardia, Cellistic is uniquely experienced in designing and optimizing manufacturing procedures for iPSCs that deliver quality products at scale. For more information, visit www.cellistic.com.